Tracers / [161Tb]Tb-AMTG

[161Tb]Tb-AMTG

Also written as [Tb-161]Tb-AMTG

Radionuclide: Tb-161 t½ 9907.2 min
Modality: Therapy
Production route: —
Stage: preclinical study
Syntheses indexed: 2

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: GRPR antagonist peptide (DOTA-conjugated α-Me-Trp8-RM2 analogue)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) antagonist PMID 38124121
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	AMTG	38124121 2024 J Nucl Med
—	—	—	—	—	AMTG	42429818 2026 Eur J Nucl Med Mol Imaging 161Tb- and 177Lu-Labeling was completed at 90 °C within 10 min (1.0 M sodium acetate buffer, pH = 5.5, molar activity of ~ 50 MBq/nmol)

Need this precursor?We can point you to suppliers for [161Tb]Tb-AMTG, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38124121: 'AMTG (α-Me-Trp8-RM2)'. Stage set/updated at stage 23 from PMID 38124121: 'Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study.'.